355 related articles for article (PubMed ID: 15563479)
1. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Olsson A; Vanderstichele H; Andreasen N; De Meyer G; Wallin A; Holmberg B; Rosengren L; Vanmechelen E; Blennow K
Clin Chem; 2005 Feb; 51(2):336-45. PubMed ID: 15563479
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.
Reijn TS; Rikkert MO; van Geel WJ; de Jong D; Verbeek MM
Clin Chem; 2007 May; 53(5):859-65. PubMed ID: 17395712
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
4. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.
Wang LS; Leung YY; Chang SK; Leight S; Knapik-Czajka M; Baek Y; Shaw LM; Lee VM; Trojanowski JQ; Clark CM
J Alzheimers Dis; 2012; 31(2):439-45. PubMed ID: 22571982
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.
Irwin DJ; McMillan CT; Toledo JB; Arnold SE; Shaw LM; Wang LS; Van Deerlin V; Lee VM; Trojanowski JQ; Grossman M
Arch Neurol; 2012 Aug; 69(8):1018-25. PubMed ID: 22490326
[TBL] [Abstract][Full Text] [Related]
8. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.
Kang JH; Korecka M; Toledo JB; Trojanowski JQ; Shaw LM
Clin Chem; 2013 Jun; 59(6):903-16. PubMed ID: 23519967
[TBL] [Abstract][Full Text] [Related]
10. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
12. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
[TBL] [Abstract][Full Text] [Related]
15. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
16. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
17. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N; Andreasson U; Persson S; Arai H; Batish SD; Bernardini S; Bocchio-Chiavetto L; Blankenstein MA; Carrillo MC; Chalbot S; Coart E; Chiasserini D; Cutler N; Dahlfors G; Duller S; Fagan AM; Forlenza O; Frisoni GB; Galasko D; Galimberti D; Hampel H; Handberg A; Heneka MT; Herskovits AZ; Herukka SK; Holtzman DM; Humpel C; Hyman BT; Iqbal K; Jucker M; Kaeser SA; Kaiser E; Kapaki E; Kidd D; Klivenyi P; Knudsen CS; Kummer MP; Lui J; Lladó A; Lewczuk P; Li QX; Martins R; Masters C; McAuliffe J; Mercken M; Moghekar A; Molinuevo JL; Montine TJ; Nowatzke W; O'Brien R; Otto M; Paraskevas GP; Parnetti L; Petersen RC; Prvulovic D; de Reus HP; Rissman RA; Scarpini E; Stefani A; Soininen H; Schröder J; Shaw LM; Skinningsrud A; Skrogstad B; Spreer A; Talib L; Teunissen C; Trojanowski JQ; Tumani H; Umek RM; Van Broeck B; Vanderstichele H; Vecsei L; Verbeek MM; Windisch M; Zhang J; Zetterberg H; Blennow K
Alzheimers Dement; 2011 Jul; 7(4):386-395.e6. PubMed ID: 21784349
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
20. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
